Roger D.  Dansey net worth and biography

Roger Dansey Biography and Net Worth

Insider of Seagen
Roger joined Seagen as Chief Medical Officer in 2018, bringing extensive experience in cancer drug development. His deep oncology background and proven leadership has helped Seagen evolve into a global, multi-product oncology company.

Previously, Roger was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda® (pembrolizumab) across multiple tumor types. Earlier in his career, Roger was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva® (denosumab) at Amgen, where he held multiple roles in oncology and hematology.

Roger holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa. He serves as a member of the board of directors for INOVIO Pharmaceuticals, Inc.

What is Roger D. Dansey's net worth?

The estimated net worth of Roger D. Dansey is at least $26.69 million as of September 21st, 2023. Dr. Dansey owns 116,677 shares of Seagen stock worth more than $26,688,697 as of March 28th. This net worth estimate does not reflect any other assets that Dr. Dansey may own. Additionally, Dr. Dansey receives an annual salary of $2,480,000.00 as Insider at Seagen. Learn More about Roger D. Dansey's net worth.

How old is Roger D. Dansey?

Dr. Dansey is currently 67 years old. There are 5 older executives and no younger executives at Seagen. Learn More on Roger D. Dansey's age.

What is Roger D. Dansey's salary?

As the Insider of Seagen Inc., Dr. Dansey earns $2,480,000.00 per year. Learn More on Roger D. Dansey's salary.

How do I contact Roger D. Dansey?

The corporate mailing address for Dr. Dansey and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Roger D. Dansey's contact information.

Has Roger D. Dansey been buying or selling shares of Seagen?

Roger D. Dansey has not been actively trading shares of Seagen in the last ninety days. Learn More on Roger D. Dansey's trading history.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Are insiders buying or selling shares of Seagen?

In the last twelve months, insiders at the biotechnology company sold shares 28 times. They sold a total of 162,022 shares worth more than $33,110,171.31. The most recent insider tranaction occured on November, 10th when CEO David R Epstein sold 10,620 shares worth more than $2,262,166.20. Insiders at Seagen own 25.9% of the company. Learn More about insider trades at Seagen.

Information on this page was last updated on 11/10/2023.

Roger D. Dansey Insider Trading History at Seagen

See Full Table

Roger D. Dansey Buying and Selling Activity at Seagen

This chart shows Roger D. Dansey's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $228.74
Low: $228.74
High: $228.74

50 Day Range

MA: $228.74
Low: $228.74
High: $228.74

2 Week Range

Now: $228.74
Low: $123.77
High: $228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32